A Phase I Study of the HER1, HER2 Dual Kinase Inhibitor, Lapatinib Plus the Proteosomal Inhibitor Bortezomib in Patients With Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 19 Feb 2016
At a glance
- Drugs Bortezomib (Primary) ; Lapatinib (Primary)
- Indications Cancer
- Focus Adverse reactions
- 29 Sep 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 15 Feb 2015 Planned End Date changed from 1 Dec 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov record.
- 29 Dec 2011 New trial record